Skip to main content

A World-Leading Psychedelic Supply Chain Solution

Psygen’s progressive business model is primarily focused on the large-scale manufacture of GMP psychedelic APIs. With existing Contract Manufacturing Organizations (CMOs) lacking expertise and infrastructure to produce at scale – and often manufacturing in non-dedicated facilities under restrictive exclusivity agreements — the current supply chain is insufficient to meet the industry’s growing needs.

Introduction

Psygen will be publicly listed and fully operational in 2022 – investing back into its development program and enabling the production of pharmaceutical-grade psychedelics at scale.

Our Story

Ryan Zurrer of Vine Ventures interviews Peter van der Heyden & Danny Motyka, discussing their founding vision.

Ryan, one of Psygen’s initial investors who has a significant shareholder position, has been a venture capitalist for a decade. Ryan launched Vine Ventures in 2019 to invest broadly across the emerging psychedelics landscape. Vine is the leading venture firm in psychedelics.

Press Releases

Subscribe to our newsletter for the latest news & updates.

    Loading...